HSBC Global Research has updated its recommendations and price targets for several major European pharmaceutical companies following a comprehensive review of the sector, signalling both selective optimism and heightened caution about near-term headwinds.
The broker reduced its target price for AstraZeneca to '
Specifically, HSBC trimmed AstraZeneca's target to
HSBC retained a "buy" rating for AstraZeneca while reducing the target from
HSBC noted that upcoming readouts for camizestrant (SERENA-4) and Dato-DXd (AVANZAR) represent "key overhangs on the sentiment," but said it still sees pipeline depth and balance sheet capacity to support dealmaking. The broker lowered AstraZeneca revenue estimates by 2.1% for both 2026 and 2027. At the close of trading on July 3 the stock stood at 14,456p, which HSBC said left roughly 14.2% of potential upside to its target.
GSK's recommendation was moved up to "hold" from "reduce," and the broker raised its target price to
HSBC pointed to management change and a "recent willingness to reinvest in the pipeline" as signs that GSK "might be turning a corner," while cautioning that the company's patent cliff issue remains unresolved. The broker added that "the catalysts for de-rating of the stock are limited." On July 3 the stock closed at 2,015p, which HSBC said implied roughly 7.7% to the price target.
Roche Holding saw its rating cut to "hold" from "buy" with the target price unchanged at CHF365. HSBC explained that consensus estimates have been updated to better reflect expected pipeline revenues from giredestrant and fenebrutinib, removing the central element of its prior bullish case. Roche closed at CHF346.20 on July 3, leaving about 5.4% upside to the bank's target.
Merck KGaA was also downgraded to "hold" from "buy," though HSBC raised the company's target to
The bank said the Process Solutions recovery appears to have been partly pulled forward because of supply-chain destocking, and warned of "difficult comps and de-stocking" likely to follow after the third quarter of 2026. HSBC also commented on the possible acquisition of Bio-Techne, saying the valuation "seems rich" and that returns would be accretive only under the most bullish scenarios. Merck KGaA closed at and HSBC's target implied approximately 16.7% upside as of July 3.
Sanofi retained a "buy" rating with a target; HSBC said that a partnership with Regeneron combined with potential further M&A "could shift the narrative on the stock driving multiples normalisation." At on July 3 Sanofi was trading about 25.3% below HSBC's target.
Bayer kept its "buy" recommendation and a target price. The stock closed at on July 3, giving roughly 12.4% upside to the bank's target, after jumping 8.90% on July 2 following a favorable Supreme Court verdict. HSBC noted that litigation liabilities for the company were capped at $7.25 billion.
Overall, HSBC's review combined targeted downgrades with selective upgrades and reiterated the need to balance pipeline prospects and balance-sheet strength against deal valuations and rising capital intensity across the pharmaceutical sector.
Note: All price points, ratings and closing values are as reported by HSBC and reflect the position as of July 3 referenced in the bank's review.